<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0901244690
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Korsuva
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DIFELIKEFALIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        µ/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1950.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Siegfried Hameln GmbH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Siegfried Hameln GmbH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 718]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ARAC HEALTHCARE
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Vifor Fresenius Medical Care Renal Pharma
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        V03AX
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Korsuva&reg; contains the active substance difelikefalin. It is used to treat itching in adults with chronic kidney disease who need dialysis to clean their blood.</p><p><br />Korsuva&reg; works at targets in the body called kappa-opioid receptors which are involved in controlling the perception of itching. By stimulating these receptors on nerves and immune cells outside the brain, Korsuva&reg; relieves the sensation of itch caused by chronic kidney disease. The active substance Difelikefalin does not pass the blood-brain barrier (the natural protective barrier between blood vessels and the brain), which reduces the risk of side effects.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Korsuva&reg;</strong><br />if you are allergic to Difelikefalin or any of the other ingredients of this medicine (listed in section 6).</p><p><br /><strong>Warnings and precautions</strong><br />&bull; Talk to your doctor or nurse before you are given Korsuva&reg; if you:<br />&bull; have an increased potassium level in the blood<br />&bull; have or have had heart weakness or a heart rhythm disorder</p><p>&bull; have reduced function of the blood-brain barrier (such as cancer in the brain or the central nervous system, or a disease of the central nervous system like multiple sclerosis or dementia) as this might increase your risk of side effects<br />&bull; are 65 years of age or older, as you may be more likely to be made drowsy by the medicine<br />&bull; are using medicines that could increase the risk of drowsiness or dizziness, such as:<br />- medicines that slow down brain activity such as those that help with sleep disturbances and anxiety<br />- medicines to treat allergies, cold, nausea and/or vomiting called sedating antihistamines<br />- strong painkillers, called opioid analgesics<br />Talk to your doctor if you take any of these medicines.</p><p><br /><strong>Children and adolescents</strong><br />Korsuva&reg; is not recommended for children under 18 years, as it has not been studied in these patients.</p><p><br /><strong>Other medicines and Korsuva&reg;</strong><br />Tell your doctor if you are using, have recently used or might use any other medicines.</p><p><br /><strong>Pregnancy and breast-feeding</strong><br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before you are given Korsuva&reg;.</p><p><br />Korsuva&reg; has not been studied in pregnant women. It is unknown whether Korsuva&reg; can harm the unborn baby. Your doctor will discuss with you if you should use Korsuva&reg; during pregnancy.</p><p><br />It is not known whether Difelikefalin can pass into breast milk. If you are breast-feeding your doctor will advise you on whether to stop breast-feeding or using Korsuva&reg;, considering the benefit of breast-feeding to the baby and Korsuva&reg; to you, the mother.</p><p><br /><strong>Driving and using machines</strong><br />Korsuva&reg; can cause drowsiness and dizziness which may affect your ability to react. Do not drive or use machines if your ability to react is reduced or you do not know the effect of Korsuva&reg; on your ability to react.</p><p><br /><strong>Korsuva&reg; contains sodium</strong><br />This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The doctor will work out the right dose of Korsuva&reg; for you, based on your body weight. It will be given as an injection into a vein by a doctor or nurse at the end of your dialysis treatment through the tube that connects you to the dialysis machine.</p><p><br />Korsuva&reg; will be given 3 times per week. This increases to 4 times per week in case of a fourth dialysis. No more than 4 doses are recommended, even if the number of dialysis treatments in a week is more than 4.</p><p><br />If a dialysis treatment is unfinished, your doctor will decide whether it is better for you to receive Korsuva&reg; after the unfinished dialysis session or wait until your next dialysis treatment.</p><p>If a dialysis treatment is missed, the usual dose of Korsuva&reg; will be given to you at the next dialysis treatment.</p><p><br />Itching is expected to decrease after 2-3 weeks treatment with Korsuva&reg;.</p><p><br /><strong>Patients with reduced liver function</strong><br />No dose adjustment is required for patients with mild or moderate reduced liver function. Korsuva&reg; is not recommended for patients with severely reduced liver function, as use has not been studied in these patients.</p><p><br /><strong>If you have been given more Korsuva&reg; than you should</strong><br />This increases the occurrence of side effects listed in section 4. Inform your doctor if you think this applies to you.</p><p><br />If you have any further questions on the use of this medicine, ask your doctor or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><br />The following side effects have been reported in patients receiving this medicine:<br /><strong>Common,</strong> may affect up to 1 in 10 people:<br />&bull; drowsiness<br />&bull; sensation disorder in the skin such as tingling, prickling, burning or numbness, decreased feeling or sensitivity</p><p><br /><strong>Uncommon,</strong> may affect up to 1 in 100 people:<br />&bull; dizziness<br />&bull; headache<br />&bull; changes in mental status (alertness and clarity of thought), including confusion<br />&bull; nausea, vomiting<br />&bull; diarrhoea</p><p><br /><strong>Reporting of side effects</strong><br />If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p><br />Do not use this medicine after the expiry date which is stated on the label and carton after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p><br />This medicine does not require any special storage conditions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is difelikefalin.<br />&bull; Each vial contains 50 micrograms of Difelikefalin (as acetate) in 1.0 mL solution.<br />&bull; The other ingredients are acetic acid (for pH adjustment), sodium acetate trihydrate (for pH adjustment), sodium chloride, water for injections. See section 2 &ldquo;Korsuva&reg; contains sodium&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Korsuva® is a clear, colourless solution and free from particles (pH 4.5). It is supplied in a glass vial with rubber stopper, an aluminium seal and a blue flip-off plastic cap.

Pack sizes of 3 and 12 vials.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong><br />Vifor Fresenius Medical Care Renal Pharma France<br />100&ndash;101 Terrasse Boieldieu, Tour Franklin La D&eacute;fense 8, 92042 Paris La D&eacute;fense Cedex, France</p><p><br /><strong>Bulk Manufacturing, Primary, secondary packaging and Quality Control site</strong><br />Siegfried Hameln GmbH Langes Feld 13 31789 Hameln, Germany</p><p><br /><strong>Batch Releasing site</strong><br />Vifor France, 100-101 Terrasse Boieldieu, Tour Franklin La D&eacute;fense 8, 92042 Paris La D&eacute;fense Cedex,<br />France</p><p><br />For any information about this medicine, please contact the local representative of the Marketing<br />Authorisation Holder.<br />Name: ARAC Healthcare<br />Adress City: Riyadh<br />Tel: + 966 11 417 1596<br />e-mail: Drug.safety@arac.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Leaflet revision date: August 2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي كورسوڤا&reg;على المادة الفعالة ديفيليكفالين. ويستخدم لعلاج الحكة لدى البالغين المصابين بالأمراض الكلوية المزمنة الذين<br />يحتاجون إلى غسيل الكلى لتنقية الدم .</p><p><br />يعمل كورسوڤا&reg; على أهداف في الجسم تسمى مستقبلات كابا الأفيونية التي تشارك في عملية التحكم في الإحساس بالحكة. ومن خلال<br />تحفيز هذه المستقبلات على الأعصاب والخلايا المناعية خارج الدماغ يخفف كورسوڤا&reg; من الشعور بالحكة الناجم عن الإصابة ،<br />بالأمراض الكلوية المزمنة. لا تعبر المادة الفعالة ديفيليكفالين الحاجز الدموي الدماغي (الحاجز الواقي الطبيعي الموجود بين الأوعية<br />الدموية والدماغ)، مما يقلل من مخاطر الإصابة بالآثار الجانبية .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr">&reg;لا تستخدم كورسوڤا<br />.( إذا كنت مصابًا بالحساسية تجاه ديفيليكفالين أو أي مكون آخر من مكونات هذا الدواء (المدرجة في القسم 6</p><p><br /><strong>التحذيرات والاحتياطات</strong><br />&nbsp;&bull;&nbsp; تحدث إلى طبيبك أو الممرضة قبل تلقي كورسوڤا&reg;إذا:<br />&bull; كنت تعاني من زيادة في مستويات البوتاسيوم في الدم<br />&bull; كنت مصابًا حاليا أو أصبت سابقًا بضعف في القلب أو اضطراب في نظم القلب<br />&bull; كان لديك قصور في وظيفة الحاجز الدموي الدماغي (مثل الإصابة بسرطان في الدماغ أو الجهاز العصبي المركزي أو<br />مرض في الجهاز العصبي المركزي مثل التصلب المتعدد أو الخرف) لأن ذلك قد يزُيد من مخاطر إصابتك بالآثار<br />الجانبية<br />&bull; كنت تبلغ 65 عامًا أو أكبر، فقد تكون أكثر عرضة للشعور بالنعاس بسبب الدواء</p><p>كنت تستخدم أدوية من شأنها زيادة مخاطر الإصابة بالخمول أو الدوخة، مثل:<br />- الأدوية التي تبطئ نشاط الدماغ مثل تلك التي تساعد في علاج اضطرابات النوم والقلق<br />- الأدوية المستخدمة لعلاج حالات الحساسية و/أو البرد و/أو الغثيان و/أو القيء التي يطلق عليها مضادات الهيستامين المهدئة<br />- مسكنات الألم القوية التي تسمى المسكنات الأفيونية<br />تحدث إلى طبيبك في حالة تناولك أي من هذه الأدوية .</p><p><br /><strong>الأطفال والمراهقو ن</strong><br />لا يوُصى باستخدام كورسوڤا&reg;مع الأطفال الذين تقل أعمارهم عن 18 عامًا نظرًا لعدم دراسة استخدامه&nbsp;مع هؤلاء المرضى .</p><p><br /><strong>الأدوية الأخرى وكورسوڤا&reg;</strong><br />أخبر طبيبك إذا كنت تستخدم أو استخدمت مؤخرًا أو قد تستخدم أي أدوية أخرى .</p><p><br /><strong>الحمل والرضاعة الطبيعية</strong><br />إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية أو تعتقدين أنكِ ربما تكونين حاملًا أو كنتِ تخططين للحمل، فاستشیري طبيبكِ قبل تلقي<br />كورسوڤا&reg;,</p><p><br />لم تتم دراسة استخدام كورسوڤا &reg;مع السيدات الحوامل. ومن غير المعروف ما إذا كان كورسوڤا &reg; يمكنه&nbsp;أن يؤذي الجنين أم لا.<br />سيناقش طبيبكِ معكِ ما إذا كان ينبغي لكِ استخدام كورسوڤا&reg;&nbsp;أثناء الحمل .</p><p><br />من غير المعروف ما إذا كان ديفيليكفالين&nbsp;يمر إلى لبن الثدي أم لا. لذا إذا كنتِ تُرضعين رضاعة طبيعية، فسينصحك طبيبكِ بما إذا كان<br />عليكِ إيقاف الرضاعة الطبيعية أم إيقاف استخدام كورسوڤا&reg; مع الأخذ في الاعتبار فائدة الرضاعة الطبيعية للطفل، وفائدة كورسوڤا ،&reg;<br />بالنسبة لكِ كأم .</p><p><br /><strong>القيادة واستخدام الآلا ت</strong><br />يمكن أن يسبب كورسوڤا&reg; الخمول والدوخة، وهو ما قد يؤثر في قدرتك على الاستجابة. فاحرص على تجنب القيادة أو استخدام الآلات<br />إذا قلّت سرعة استجابتك أو إذا كنت لا تعرف تأثير كورسوڤا&reg;في قدرتك على الاستجابة .</p><p><br /><strong>يحتوي كورسوڤا&reg;على الصوديو م</strong><br />يحتوي هذا الدواء على أقل من 1 مليمول من الصوديوم ( 23 مجم) لكل قارورة، أي أنه&nbsp;يعد &quot;خاليا من الصوديوم&quot; تقريبًا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>سيحدد الطبيب الجرعة المناسبة لك من كورسوڤا&reg;بناءً على وزن جسمك. وسيعطيها لك طبيب أو ممرضة في نهاية جلسة غسيل الكلى عن طريق الحقن في الوريد باستخدام الأنبوب الذي يوصلك بجهاز غسيل الكلى .</p><p><br />سوف تتلقى كورسوڤا&reg; 3 مرات في الأسبوع. وسيزيد هذا المعدل إلى 4 مرات في الأسبوع، في حالة الخضوع لجلسة رابعة من غسيل<br />الكلى. لا يوُصى بأكثر من 4 جرعات، حتى إذا كان عدد جلسات غسيل الكلى يزيد عن 4 مرات في الأسبوع .</p><p><br />في حالة عدم اكتمال جلسة غسيل الكلى، سيقرر طبيبك ما إذا كان من الأفضل لك تلقي كورسوڤا&reg;بعد جلسة غسيل الكلى غير المكتملة أم<br />الانتظار حتى جلسة غسيل الكلى المقبلة .</p><p><br />إذا فوَّت جلسة غسیل الكلى، فستتلقى الجرعة المعتادة من كورسوڤا &reg;في جلسة غسیل الكلى المقبلة .</p><p><br />يتُوقع أن تقل الحكة بعد فترة تتراوح بین أسبوعین إلى ثلاثة أسابیع من العلاج بكورسوڤا.&reg;</p><p><br /><strong>مرضى قصور وظائف الكبد</strong><br />لا توجد حاجة لتعديل الجرعات لدى المرضى المصابين بقصور خفيف أو متوسط في وظائف الكبد. لا يوصى باستخدام كورسوڤا&reg;مع<br />المرضى المصابين بقصور شديد في وظائف الكبد، نظرًا لعدم دراسة استخدامه&nbsp;مع هؤلاء المرضى .</p><p><strong>إذا تلقيت جرعة أكبر مما ينبغي من كورسوڤا&reg;</strong></p><p>يزيد هذا من حدوث الآثار الجانبية المذكورة في القسم 4. أخبر طبيبك إذا كنت تعتقد أن هذا ينطبق عليك .<br />إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، فاسأل طبيبك أو الممرضة .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كما هو الحال مع جميع الأدوية، يمكن أن يسبب ھذا الدواء آثارًا جانبية، غير أنها لا تصيب الجميع .<br />أُبلِغ عن الآثار الجانبية التالية لدى المرضى الذین يتلقون هذا الدواء :<br /><strong>شائعة</strong>، قد تصيب ما يصل إلى شخص واحد من بين كل 10 أشخاص:<br />&bull; الخمول<br />&bull; اضطرابات حسية في الجلد مثل، الشعور بالتنميل أو الوخز أو الحرقة أو الخدر أو نقص الحِس أو القدرة على الشعو ر<br /><strong>غير شائعة،</strong> قد تصيب ما يصل إلى شخص واحد من بين كل 100 شخص:<br />&bull; الدوخة<br />&bull; الصداع<br />&bull; تغيرات في الحالة النفسية (اليقظة ووضوح الأفكار)، بما في ذلك الارتباك<br />&bull; الغثيان، القيء<br />&bull; الإسهال</p><p><br /><strong>الإبلاغ عن الآثار الجانبية</strong><br />في حالة إصابة المريض بأيّ آثار جانبية، ينبغي استشارة الطبيب أو الممرضة. يتضمن هذا أي آثار جانبية محتملة غير مدرجة في هذه<br />النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احتفظ بهذا الدواء بعيدًا عن مرأى ومتناول الأطفال .<br />لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على الملصق والعبوة الكرتونية بعد الرمز &quot;EXP&quot;. يشير تاريخ انتهاء<br />الصلاحية إلى آخر يوم من الشهر المذكور .<br />لا يتطلب هذا الدواء أي ظروف خاصة للتخزين .<br />يحفظ في درجة حرارة أقل من ۳۰ درجة مئوية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي ديفيليكفالين.<br />&bull; تحتوي كل قارورة على 50 ميكروجرامًا من ديفيليكفالين (في صورة أسيتات) في حجم 1.0 مل من المحلول .<br />&bull; والمواد الأخرى هي حمض الأستيك (لتعديل درجة الحموضة)، ثلاثي هيدرات أسيتات الصوديوم (لتعديل درجة<br />الحموضة)، كلوريد الصوديوم، ماء للحقن. انظر القسم 2 &quot;يحتوي كورسوڤا&reg;&nbsp;على الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>كورسوڤا &reg;هو محلول صافٍ عديم اللون وخالٍ من الجسيمات (بدرجة حموضة 4.5 ). ويتوفر في قارورة زجاجية ذات سدادة مطاطية<br />ومانع تسرب من الألومنيوم وغطاء بلاستيكي أزرق اللون يفتح لأعلى .</p><p>أحجام العبوات هي عبوة سعة 3 قوارير وعبوة سعة 12 قارورة .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr">صاحب الترخيص التسويقي<br />Vifor Fresenius Medical Care Renal Pharma France<br />100&ndash;101 Terrasse Boieldieu, Tour Franklin La D&eacute;fense 8, 92042 Paris La D&eacute;fense Cedex, France<br />موقع التصنيع والتعبئة ومراقبة الجودة<br />Siegfried Hameln GmbH Langes Feld 13 31789 Hameln, Germany<br />موقع إصدار الدفعا ت<br />Vifor France, 100-101 Terrasse Boieldieu, Tour Franklin La D&eacute;fense 8, 92042 Paris La D&eacute;fense Cedex,<br />France<br />للحصول على أي معلومات بشأن هذا الدواء، يرجى الاتصال بالوكيل المحلي للشركة الحاملة<br />لتصريح التسويق .<br />ARAC Healthcare : الاسم<br />Riyadh ,عنوان المدینة : الريا ض<br />+966 11 417 Druالهاتف: 1596<br />Drug.safety@arac.sa:البريد الإلكتروني</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تاریخ مراجعة النشرة: أغسطس 2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Korsuva® 50 micrograms/mL solution for injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial of 1 mL contains 50 micrograms difelikefalin (as acetate).
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection.
Clear, colourless solution, free from particles (pH 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Korsuva is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney<br />disease in adult patients on haemodialysis (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Korsuva should be restricted for in-centre haemodialysis use only.<br />Korsuva is intended for use by healthcare professionals experienced in the diagnosis and treatment of<br />conditions for which difelikefalin is indicated. Causes of pruritus other than chronic kidney disease<br />should be excluded before initiating treatment with difelikefalin.</p><p><br /><u>Posology</u></p><p><br />Difelikefalin is administered 3 times per week by intravenous bolus injection into the venous line of<br />the dialysis circuit at the end of the haemodialysis treatment during rinse-back or after rinse-back.</p><p><br />The recommended dose of difelikefalin is 0.5 micrograms/kg dry body weight (i.e., the target<br />postdialysis weight). The total dose volume (mL) required from the vial should be calculated as<br />follows: 0.01 &times; dry body weight (kg), rounded to the nearest tenth (0.1 mL). For patients with a dry<br />body weight equal to or above 195 kg the recommended dose is 100 micrograms (2 mL). Injection<br />volumes are detailed in the table below:</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td style="text-align:center; width:235px">Weight range<br />(Dry body weight in kg)</td><td style="text-align:center; width:263px">Injection volume1<br />(mL)</td></tr><tr><td style="text-align:center; width:235px">40-44</td><td style="text-align:center; width:263px">0.4</td></tr><tr><td style="text-align:center; width:235px">45-54</td><td style="text-align:center; width:263px">0.5</td></tr><tr><td style="text-align:center; width:235px">55-64</td><td style="text-align:center; width:263px">0.6</td></tr><tr><td style="text-align:center; width:235px">65-74</td><td style="text-align:center; width:263px">0.7</td></tr><tr><td style="text-align:center; width:235px">75-84</td><td style="text-align:center; width:263px">0.8</td></tr><tr><td style="text-align:center; width:235px">85-94</td><td style="text-align:center; width:263px">0.9</td></tr><tr><td style="text-align:center; width:235px">95-104</td><td style="text-align:center; width:263px">1.0</td></tr><tr><td style="text-align:center; width:235px">105-114</td><td style="text-align:center; width:263px">1.1</td></tr><tr><td style="text-align:center; width:235px">115-124</td><td style="text-align:center; width:263px">1.2</td></tr><tr><td style="text-align:center; width:235px">125-134</td><td style="text-align:center; width:263px">1.3</td></tr><tr><td style="text-align:center; width:235px">135-144</td><td style="text-align:center; width:263px">1.4</td></tr><tr><td style="text-align:center; width:235px">145-154</td><td style="text-align:center; width:263px">1.5</td></tr><tr><td style="text-align:center; width:235px">155-164</td><td style="text-align:center; width:263px">1.6</td></tr><tr><td style="text-align:center; width:235px">165-174</td><td style="text-align:center; width:263px">1.7</td></tr><tr><td style="text-align:center; width:235px">175-184</td><td style="text-align:center; width:263px">1.8</td></tr><tr><td style="text-align:center; width:235px">185-194</td><td style="text-align:center; width:263px">1.9</td></tr><tr><td style="text-align:center; width:235px">&ge; 195</td><td style="text-align:center; width:263px">2.0</td></tr></tbody></table><p>1 More than 1 vial may be necessary if an injection volume of more than 1 mL is required.</p><p>An effect of difelikefalin in reducing pruritus is expected after 2-3 weeks of treatment.</p><p><br /><em>Missed doses</em></p><p><br />If a regularly scheduled haemodialysis treatment is missed, Korsuva should be administered at the<br />next haemodialysis treatment at the same dose.</p><p><br /><em>Extra treatment</em></p><p><br />If a 4th haemodialysis treatment is performed in a week, Korsuva should be administered at<br />the end of the haemodialysis per the recommended dose. No more than 4 doses per week<br />should be administered even if the number of haemodialysis treatments in a week exceeds 4. A<br />4th dose of Korsuva is unlikely to lead to accumulation of difelikefalin that would be of<br />concern for safety, as the majority of remaining difelikefalin from the previous treatment will<br />be cleared by haemodialysis (see sections 4.9 and 5.2). However, safety and efficacy of a 4th<br />dose has not been fully established due to insufficient data.</p><p><br /><em>Patients with incomplete haemodialysis treatment</em></p><p><br />For haemodialysis treatments less than 1 hour, administration of difelikefalin should be withheld until<br />the next haemodialysis session.<br />Following administration of difelikefalin in haemodialysis subjects, up to 70% is eliminated from the<br />body prior to the next haemodialysis session (see sections 4.9 and 5.2). Difelikefalin plasma level<br />remaining at the time of the next haemodialysis is reduced by about 40-50% within one hour of<br />haemodialysis.</p><p><br /><em>Patients with hepatic impairment</em></p><p><br />No dose adjustment is required for patients with mild or moderate hepatic impairment (see section<br />5.2). Difelikefalin has not been studied in subjects with severe hepatic impairment (National Cancer<br />Institute (NCI) Organ Dysfunction Working Group (ODWG)) and is therefore not recommended for<br />use in this patient population.</p><p><br /><em>Elderly population</em> (&ge; 65 years of age)</p><p><br />Dosing recommendations for elderly patients are the same as for adult patients.</p><p><br /><em>Paediatric population</em></p><p>The safety and efficacy of difelikefalin in children aged 0-17 years has not yet been established.<br />No data are available.</p><p><br /><u>Method of administration</u></p><p><br />Korsuva should not be diluted and should not be mixed with other medicinal products.</p><p><br />Difelikefalin is removed by the dialyzer membrane and must be administered after blood is no longer<br />circulating through the dialyzer. Difelikefalin is administered 3 times per week by intravenous bolus<br />injection into the venous line of the dialysis circuit at the end of the haemodialysis treatment during<br />rinse-back or after rinse-back.<br />When given after rinse-back, at least 10 mL of sodium chloride 9 mg/mL (0.9%) solution for injection<br />rinse-back volume should be administered after injection of Korsuva. If the dose is given during<br />rinse-back, no additional sodium chloride 9 mg/mL (0.9%) solution for injection is needed to flush the<br />line.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hyperkalaemia</u></p><p><br />Hyperkalaemia frequently occurs in chronic kidney disease patients on haemodialysis. In the placebocontrolled<br />clinical studies a numerically higher rate of adverse events of hyperkalaemia was reported<br />for the difelikefalin treated patients (4.7%; 20 / 424 patients) compared to placebo (3.5%; 15 / 424<br />patients). No causal relationship was established. Frequent monitoring of potassium levels is<br />recommended.</p><p><br /><u>Cardiac failure and atrial fibrillation</u></p><p><br />Difelikefalin has not been studied in patients with New York Heart Association class IV heart failure.<br />In the pivotal clinical studies a small numerical imbalance of cardiac failure and atrial fibrillation<br />events was observed in the difelikefalin treated patients compared to placebo, in particular among<br />patients with a medical history of atrial fibrillation who discontinued or missed their atrial fibrillation<br />treatment. No causal relationship was established.</p><p><br /><u>Patients with impaired blood-brain barrier</u></p><p><br />Difelikefalin is a peripherally acting kappa opioid receptor agonist with restricted access to the central<br />nervous system (CNS). The blood-brain barrier (BBB) integrity is important for minimizing<br />difelikefalin uptake into the CNS (see section 5.1). Patients with clinically important disruptions to the<br />BBB (e.g., primary brain malignancies, CNS metastases or other inflammatory conditions, active<br />multiple sclerosis, advanced Alzheimer&rsquo;s disease) may be at risk for difelikefalin entry into the CNS.<br />Korsuva should be prescribed with caution in such patients taking into account their individual<br />benefit-risk balance with observation for potential CNS effects.</p><p><br /><u>Dizziness and somnolence</u></p><p><br />Dizziness and somnolence have occurred in patients taking difelikefalin and may subside over time<br />with continued treatment (see section 4.8). Concomitant use of sedating antihistamines, opioid<br />analgesics or other CNS depressants may increase the likelihood of these adverse reactions and should<br />be used with caution during treatment with difelikefalin (see section 4.5).<br />Compared to placebo, the incidence of somnolence was higher in difelikefalin treated subjects<br />65 years of age and older (7.0%) than in difelikefalin treated subjects less than 65 years of age (2.8%).</p><p><u>Excipients with known effect</u></p><p><br />This medicinal product contains less than 1 mmol sodium per vial, that is to say essentially sodium-free.<br /><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No clinical interaction studies have been performed. Difelikefalin does not inhibit or induce CYP450<br />enzymes and is not a substrate of CYP450 enzymes. It is not an inhibitor of glucuronidating enzymes<br />either. Difelikefalin is not a substrate or an inhibitor of human transporters (see section 5.2).<br />Therefore, interactions of difelikefalin with other medicinal products are unlikely.<br />Concurrent administration of medicinal products such as sedating antihistamines, opioid analgesics or<br />other CNS depressants (e.g., clonidine, ondansetron, gabapentin, pregabalin, zolpidem, alprazolam,<br />sertraline, trazodone) may increase the likelihood of dizziness and somnolence (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p><br />There are no or limited amount of data from the use of difelikefalin in pregnant women.<br />Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity<br />(see section 5.3).</p><p><br />As a precautionary measure, it is preferable to avoid the use of Korsuva during pregnancy.</p><p><br /><u>Breast-feeding</u><br />It is unknown whether difelikefalin is excreted in human breast milk.</p><p><br />A risk to the newborns/infants cannot be excluded.</p><p><br />A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from<br />Korsuva therapy taking into account the benefit of breast-feeding for the child and the benefit of<br />therapy for the woman.</p><p><br />Animal studies have shown excretion of difelikefalin in breast milk.</p><p><br /><u>Fertility</u><br />There are no data on the effect of difelikefalin on fertility in humans. In rat studies with difelikefalin,<br />there was no effect on fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Korsuva has minor influence on the ability to drive and use machines.<br />Somnolence and/or dizziness have been reported in patients receiving difelikefalin (see section 4.8).<br />Patients should be cautioned about driving or operating hazardous machinery until the effect of<br />difelikefalin on the patient&rsquo;s ability to drive or operate machinery is known. Somnolence occurred<br />within the first 3 weeks of treatment and tended to subside with continued dosing. Dizziness occurred<br />within the first 9 weeks of treatment and was generally transient.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>In placebo controlled and uncontrolled phase 3 clinical studies, approximately 6.6% of the patients<br />experienced at least one adverse reaction during difelikefalin treatment. The most common adverse<br />reactions were somnolence (1.1%), dizziness (0.9%), paraesthesia (including hypoesthesia,<br />paraesthesia oral and hypoesthesia oral) (1.1%), headache (0.6%), nausea (0.7%), vomiting (0.7%),<br />diarrhoea (0.2%) and mental status changes (including confusional state) (0.3%). Most of these<br />events were mild or moderate in severity, did not lead to deleterious consequences, and resolved<br />with ongoing therapy. No event was serious and the incidence of events leading to treatment<br />discontinuation was &le; 0.5% for any of the adverse reactions listed above.</p><p><br /><u>Tabulated list of adverse reactions</u></p><p><br />The adverse reactions observed in the placebo-controlled and uncontrolled phase 3 clinical studies in<br />patients (N = 1306) treated with difelikefalin are listed in Table 1 by MedDRA system organ class,<br />preferred term and frequency.</p><p><br />The frequency is classified as common (&ge; 1/100 to &lt; 1/10) and uncommon (&ge; 1/1,000 to &lt; 1/100).</p><p><br />Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>Table 1: Adverse reactions attributed to the treatment with difelikefalin in haemodialysis<br />patients</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td style="text-align:center; width:170px">MedDRA System Organ Class</td><td style="text-align:center; width:158px">Common</td><td style="text-align:center; width:170px">Uncommon</td></tr><tr><td style="text-align:center; width:170px">Psychiatric disorders</td><td style="text-align:center; width:158px">&nbsp;</td><td style="text-align:center; width:170px">Mental status changes1</td></tr><tr><td style="text-align:center; width:170px">Nervous system disorders</td><td style="text-align:center; width:158px">Somnolence,&nbsp;Paraesthesia2<br />&nbsp;</td><td style="text-align:center; width:170px">Dizziness; Headache</td></tr><tr><td style="text-align:center; width:170px">Gastrointestinal disorders</td><td style="text-align:center; width:158px">&nbsp;</td><td style="text-align:center; width:170px"><br />Nausea; Diarrhoea</td></tr></tbody></table><p>1 Mental status changes included MedDRA preferred terms of confusional state and mental status changes.<br />2 Paraesthesia included MedDRA preferred terms of paraesthesia, hypoesthesia, paraesthesia oral and hypoesthesia oral.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p><br /><em>Somnolence</em></p><p><br />Somnolence was reported as treatment emergent adverse event in 2.2% of subjects randomised to<br />difelikefalin. The vast majority of these events was mild or moderate in severity. In 0.3% of patients,<br />somnolence led to discontinuation of treatment with difelikefalin. Somnolence was reported as serious<br />adverse event in &lt;0.1% of difelikefalin treated subjects. In 1.1% of patients, somnolence was reported<br />to have a causal relationship to difelikefalin treatment. Somnolence occurred within the first 3 weeks<br />of treatment and tended to subside with continued dosing.<br />The likelihood of somnolence may increase when difelikefalin is concomitantly used with other<br />medicinal products (see sections 4.4 and 4.5).</p><p><br /><em>Dizziness</em></p><p><br />Dizziness was reported as treatment emergent adverse event in 7.9% of subjects randomised to<br />difelikefalin. The vast majority of these events was mild or moderate in severity. In 0.5% of patients,<br />dizziness led to discontinuation of treatment with difelikefalin. Dizziness was reported as serious<br />adverse event in 0.5% of difelikefalin treated subjects. In 0.9% of patients, dizziness was reported to<br />have a causal relationship to difelikefalin treatment. Dizziness occurred within the first 9 weeks of<br />treatment and was generally transient.<br />The likelihood of dizziness may increase when difelikefalin is concomitantly used with other<br />medicinal products (see sections 4.4 and 4.5).</p><p><br /><em>Mental status changes</em></p><p>Mental status change (including confusional state) was reported as treatment emergent adverse event<br />in 4.4% of subjects randomised to difelikefalin.<br />The majority of these events was mild or moderate in severity. In less than 0.2% of patients, mental<br />status changes led to discontinuation of treatment with difelikefalin.<br />Mental status changes were reported as serious adverse event in 2.2% of difelikefalin treated subjects.<br />In 0.3% of patients, mental status changes were reported to have a causal relationship to difelikefalin<br />treatment.</p><p><br /><u>Reporting of suspected adverse reactions</u></p><p><br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It<br />allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare<br />professionals are asked to report any suspected adverse reactions.</p><p><br /><strong>To report any side effect(s):</strong><br />Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety Centre (NPC)</p><ul><li>Fax: +966-11-205-7662</li><li>Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</li><li>Toll free phone: 8002490000</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: www.sfda.gov.sa/npc</li></ul><p><br /><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Single dose of difelikefalin up to 12 times and multiple doses of difelikefalin up to 5 times the clinical<br />dose of 0.5 micrograms/kg were administered in clinical studies in patients undergoing haemodialysis.<br />A dose-dependent increase in adverse events including dizziness, somnolence, mental status changes,<br />paraesthesia, fatigue, hypertension and vomiting, was observed.<br />In the event of overdose, the appropriate medical attention based on patient&rsquo;s clinical status should be<br />provided. Haemodialysis for 4 hours using a high-flux dialyzer effectively cleared approximately<br />70-80% of difelikefalin from plasma, and difelikefalin was not detectable in plasma at the end of the<br />second of two dialysis cycles (see section 5.2).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: all other therapeutic products, other therapeutic products, ATC code:<br />V03AX04</p><p><br /><u>Mechanism of action</u></p><p><br />Difelikefalin is a selective kappa opioid receptor agonist with low central nervous system penetration.<br />The physicochemical properties of difelikefalin (hydrophilic, synthetic D-amino acid peptide with<br />high polar surface area and charge at physiological pH) minimize its passive diffusion (permeability)<br />and active transport across membranes, thus limiting penetration into the central nervous system.<br />The pathophysiology of chronic kidney disease-associated pruritus is thought to be multifactorial,<br />including systemic inflammation and an imbalance in the endogenous opioid system (e.g.,<br />overexpression of mu opioid receptors and concomitant downregulation of kappa opioid receptors).<br />Opioid receptors are known to modulate itch signals and inflammation, with kappa opioid receptor<br />activation reducing itch and producing immunomodulatory effects.</p><p>The activation of kappa opioid receptors on peripheral sensory neurons and immune cells by<br />difelikefalin are considered mechanistically responsible for the antipruritic and anti-inflammatory<br />effects.</p><p><br /><u>Clinical efficacy and safety</u></p><p><br /><em>Placebo-controlled studies</em></p><p><br />In two pivotal clinical phase-3 studies of similar double-blind, randomised, placebo-controlled design<br />(KALM-1 and KALM-2), chronic kidney disease patients on haemodialysis with moderate-to-severe<br />pruritus received either placebo or 0.5 micrograms/kg difelikefalin intravenously 3 times a week<br />following haemodialysis for 12 weeks. A maximum of 4 doses per week was allowed in patients<br />receiving an additional dialysis during a given week. The primary endpoint in both studies was the<br />percentage of patients who achieved at least a 3-point reduction from baseline in the Worst<br />Itching-Numerical Rating Scale (WI-NRS) at 12 weeks. The main secondary endpoints in both studies<br />were the percentages of patients with an improvement in the WI-NRS of at least 4 points after<br />12 weeks and the changes in itch severity and itch-related quality of life (QoL) as measured by the<br />total Skindex-10 and the 5-D Itch scale. A responder analysis based on Patient Global Impression of<br />Change was also included.<br />A total of 851 patients with moderate-to-severe pruritus (baseline WI-NRS &gt;4) were enrolled in the<br />pivotal studies. Mean age was 59 years, 33.1% were aged 65 and over and 11.1% were aged 75 and<br />over; 60% of patients were male. The baseline mean WI-NRS scores were 7.18 in both, difelikefalin<br />and placebo arms; baseline median WI-NRS scores were 7.13 (range 4.2 to 10) in difelikefalin and<br />7.13 (range 4.1 to 10) in placebo arm. Other disease characteristics at baseline were comparable in<br />difelikefalin and placebo arms: time from diagnosis of chronic kidney disease (8.22 years vs.<br />8.54 years), duration of pruritus (3.20 years vs. 3.31 years) and use of medicinal products intended to<br />relieve pruritus such as antihistamines, corticosteroids, gabapentin or pregabalin (37.5% vs. 38%).<br />Across studies, difelikefalin significantly reduced itch intensity and improved itch-related QoL over<br />12 weeks as shown in Table 2.</p><p><strong>Table 2: Summary of primary and key secondary outcomes in KALM-1 and KALM-2 at week 12</strong></p><p style="text-align:center">KALM-2(n=473)</p><table border="1" cellspacing="1" cellpadding="1" style="width:466px"><tbody><tr><td style="text-align:center; width:132px">&nbsp;</td><td rowspan="1" colspan="2" style="text-align:center; width:142px">KALM-1(n=378)</td></tr><tr><td style="text-align:center; width:132px"><strong>Endpoint by<br />end of week 12</strong></td><td style="text-align:center; width:80px">difelikefalin<br />(n = 189)</td><td style="text-align:center; width:65px">Placebo<br />(n = 189)</td><td style="text-align:center; width:122px">difelikefalin<br />(n = 237)</td><td style="text-align:center; width:74px">Placebo<br />(n = 236)</td></tr><tr><td style="text-align:center; width:132px"><strong>Primary endpoint</strong></td><td colspan="4" style="text-align:center; width:80px">&nbsp;</td></tr><tr><td style="text-align:center; width:132px"><strong>WI-NRS</strong><br />Patients with &ge; 3-point<br />improvement (%)</td><td style="text-align:center; width:80px">51.0%<br />(p &lt; 0.001)</td><td style="text-align:center; width:65px">27.6%</td><td style="text-align:center; width:122px">54.0%<br />(p = 0.02)</td><td style="text-align:center; width:74px">42.2%</td></tr><tr><td style="text-align:center; width:132px"><strong>WI-NRS</strong><br />Patients with &ge; 4-point<br />improvement (%)</td><td style="text-align:center; width:80px">38.9%<br />(p &lt; 0.001)</td><td style="text-align:center; width:65px">18.0%</td><td style="text-align:center; width:122px">41.2%<br />(p = 0.01)</td><td style="text-align:center; width:74px">28.4%</td></tr><tr><td style="text-align:center; width:132px"><strong>Skindex-10</strong><br />Change from baseline<br />[total score]</td><td style="text-align:center; width:80px">-17.2<br />(p &lt; 0.001)</td><td style="text-align:center; width:65px">-12.0</td><td style="text-align:center; width:122px">-16.6<br />(p = 0.171)</td><td style="text-align:center; width:74px">-14.8</td></tr><tr><td style="text-align:center; width:132px"><strong>5-D Itch</strong><br />Change from baseline<br />[total score]</td><td style="text-align:center; width:80px">-5.0<br />(p &lt; 0.001)</td><td style="text-align:center; width:65px">-3.7</td><td style="text-align:center; width:122px">-4.9<br />Not applicable1</td><td style="text-align:center; width:74px">-3.8</td></tr></tbody></table><p>1 Was not tested based on the hierarchical testing order.</p><p><br />Figure 1 shows the mean percentage from KALM-1 and KALM-2 with a &ge; 3-point improvement<br />from baseline in WI-NRS score by study week. Based on odds ratios, statistically significant<br />improvements favouring the difelikefalin group were seen by week 3 in KALM-1 and by week 2 in<br />KALM-2 and continued at each subsequent week through week 12 in both studies.</p><p style="text-align:center"><strong>Figure 1: Percentage of patients with &ge; 3-point improvement with respect to WI-NRS score by<br />week in KALM-1 and KALM-2 (ITT population)<br />KALM-1</strong></p><p><img src="data:image/png;base64,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" alt="" width="733" height="731" vspace="0" hspace="0" border="0" style="width:733px;height:731px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>&nbsp;</p><p><em>Open label extension studies</em></p><p><br />The effect of treatment with difelikefalin for up to 52 weeks was evaluated using the 5-D Itch Scale in<br />single arm, open label extensions of studies KALM-1 and KALM-2 including 712 patients.<br />In patients switching from placebo to difelikefalin at the end of the double-blind phase, an<br />improvement in 5-D Itch score was observed after 4 weeks of treatment, with an LS mean (SE) of the<br />change from baseline comparable to the patients receiving difelikefalin from study start: -6.0 (0.22) vs.<br />-5.7 (0.23). The improvement in 5-D Itch score was maintained in both treatment groups throughout<br />the 52-week treatment.</p><p><br /><u>Paediatric population</u></p><p><br />The European Medicines Agency has deferred the obligation to submit the results of studies with<br />difelikefalin in one or more subsets of the paediatric population in the treatment of chronic kidney<br />disease associated pruritus (see section 4.2 for information on paediatric use).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In patients with severe renal impairment undergoing haemodialysis, total body clearance of<br />difelikefalin is reduced compared to healthy subjects and plasma concentrations decrease slowly until<br />cleared during dialysis. Due to the 70-80% of difelikefalin removed during dialysis, difelikefalin is<br />administered after each haemodialysis session in these patients. The available data on interindividual<br />variability in haemodialysis subjects receiving 0.5 microgram/kg difelikefalin suggest that variability<br />of AUC can exceed 30%.</p><p><br /><u>Distribution</u></p><p><br />Plasma protein binding of difelikefalin is low to moderate, ranging from 24-32%, and remains<br />unaffected by renal impairment. Mean volume of distribution at steady state ranged from 145 to<br />189 mL/kg in healthy subjects and from 214 to 301 mL/kg in haemodialysis patients with<br />moderate-to-severe pruritus. Difelikefalin penetration into the central nervous system is limited (below<br />limit of quantification) as shown by physico-chemical, in-vitro and animal data.</p><p><br /><u>Elimination</u></p><p><br />In healthy subjects, the primary route of elimination for difelikefalin is renal, accounting for about<br />81% of the dose being excreted in urine as compared to 11% via faecal excretion. In both healthy<br />volunteers and subjects on haemodialysis, most of the dose excreted into urine and faeces was<br />unchanged difelikefalin with minor quantities of putative metabolites, none exceeding 2.5%. Mean<br />total clearance ranged from 54 to 71 mL/h/kg and mean half-lives from 2 to 3 hours. By contrast, in<br />renally impaired haemodialysis patients, elimination was predominantly via faeces, accounting on<br />average for about 59% of the dose; about 19% were recovered in dialysate and about 11% were found<br />in urine. As compared to subjects with normal renal function, mean total clearance decreased and<br />half-lives increased about 10-fold with ranges of 5.3 to 7.5 mL/h/kg and 23 to 31 hours, respectively.</p><p><br /><u>Interaction with other medicinal products</u></p><p><br />Difelikefalin is neither a substrate for CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or<br />CYP3A4, nor an inhibitor of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or<br />CYP3A4/5 and has minimal to no potential for induction of human CYP1A2, CYP2B6, or CYP3A. It<br />is not an inhibitor of glucuronidation enzymes either (UGT1A3, UGT1A9, or UGT2B7).<br />In addition, difelikefalin is not an inhibitor of BCRP, BSEP, LAT1, MATE1, MATE2-K, MRP2,<br />OAT1, OAT3, OATP1A2, OATP1B1, OATP1B3, OCT1, OCT2, OCT3, P-glycoprotein, PEPT1 or<br />PEPT2, and is not a substrate for ASBT, BCRP, BSEP, LAT1, MATE1, MATE2-K, MRP2, OAT1,<br />OAT2, OAT3, OATP1A2, OATP1B1, OATP1B3, OATP2B1, OCT1, OCT2, OCT3, OCTN1,<br />OCTN2, OST&alpha;&beta;, P-glycoprotein, PEPT1 or PEPT2.</p><p><br /><u>Linearity/non-linearity</u></p><p><br />Pharmacokinetics of difelikefalin were demonstrated to be linear and dose-proportional in healthy<br />subjects (tested over dose ranges of 1 to 40 and 1 to 20 micrograms/kg in single and repeated dose<br />studies, respectively). Steady state dose proportionality was also established in chronic kidney disease<br />patients on haemodialysis receiving repeated doses from 0.5 to 2.5 micrograms/kg, 3 times per week<br />for 1 week. However, in another study dose proportionality was observed at doses of 0.5 and<br />1 micrograms/kg, but not at the dose of 1.5 micrograms/kg. Trough plasma concentration values<br />reached steady state by the second dose and for the dose of 0.5 micrograms/kg, mean accumulation<br />ratio was 1.144 in one study based on AUC0-48h and 1.33 in another study, based on AUC0-44h; showing<br />that variability for accumulation parameters can exceed 30%.</p><p><br /><u>Characteristics in specific groups of subjects or patients</u></p><p>Based on available evidence, there is no indication that factors such as age, sex, ethnicity, or mild to<br />moderate hepatic impairment have any impact on the pharmacokinetics of difelikefalin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety<br />pharmacology, repeat-dose toxicity, genotoxicity and carcinogenic potential.</p><p><br /><u>Reproductive toxicity</u></p><p><br />In rats, male and female fertility, early embryonic, and prenatal and postnatal development were not<br />affected up to 2000-fold the human AUC. In the rabbit, prenatal development was neither impaired<br />despite marked maternal toxicity at 30-fold the human AUC.</p><p><br />Difelikefalin crosses the placenta in rats.</p><p><br /><u>Abuse and dependence potential</u></p><p><br />The abuse and dependence potential studies in the rat suggest that difelikefalin is not likely to present<br />a risk of physical dependence or abuse potential.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Acetic acid (for pH adjustment)<br />Sodium acetate trihydrate (for pH adjustment)<br />Sodium chloride<br />Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal<br />products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product does not require any special storage conditions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Korsuva is supplied in a single use 2 mL glass vial (type I), with a bromobutyl rubber stopper, an<br />aluminium seal and a blue flip-off plastic cap.<br />Pack sizes of 3 and 12 vials containing 1 mL of solution for injection.<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For single use only.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local<br />requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorization Holder

Vifor Fresenius Medical Care Renal Pharma France
100–101 Terrasse Boieldieu
Tour Franklin La Défense 8
92042 Paris la Défense Cedex
France

Bulk Manufacturing, Primary, secondary packaging and Quality Control testing site
Siegfried Hameln GmbH Langes Feld 13 31789 Hameln, Germany

Batch Releaser site
Vifor France, 100-101 Terrasse Boieldieu,Tour Franklin La Défense 8, 92042 Paris La Défense Cedex,
France


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                August 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>